NextCure director granted 2,340 stock options
NextCure, Inc. director John G. Houston reported a grant of stock options representing 2,340 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NextCure, Inc. director John G. Houston reported a grant of stock options representing 2,340 shares of common stock. These options have an exercise price of $2.0200 per share and expire on June 17, 2036.
The option vests in full on the earlier of June 18, 2027 and the date of NextCure’s 2027 Annual Meeting of Stockholders, making this a routine, compensation-related award rather than an open-market purchase or sale. Following this grant, Houston holds options for 2,340 shares directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 2,340 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
Grant, award, or other acquisition financial
Annual Meeting of Stockholders financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NextCure (NXTC) director John G. Houston report in this Form 4?
What is the exercise price of John G. Houston’s NextCure (NXTC) stock options?
When do John G. Houston’s NextCure (NXTC) stock options vest?
When do John G. Houston’s NextCure (NXTC) stock options expire?
How many NextCure (NXTC) derivative securities does John G. Houston hold after this grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.